Critics argue that market exclusivity can lead to monopolistic practices and high drug prices, potentially putting life-saving treatments out of reach for many patients. There is also concern that some companies may engage in strategies such as evergreeningâmaking slight modifications to extend exclusivity periods and delay generic competition.
